# Study of Poziotinib in Japanese Patients With NSCLC

> **NCT04402008** · PHASE1,PHASE2 · TERMINATED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 42 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Poziotinib Once Daily Dosing
- **DRUG:** Poziotinib Twice Daily Dosing
- **DRUG:** Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1

## Key facts

- **NCT ID:** NCT04402008
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-23
- **Primary completion:** 2023-02-15
- **Final completion:** 2023-02-15
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Business decision, not related to safety.
- **Last updated:** 2024-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04402008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04402008, "Study of Poziotinib in Japanese Patients With NSCLC". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04402008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*